23 May Q1 2024 Key Financial Figures – Earnings before Interest, Taxes, Depreciation and Amortization (ΕΒΙΤDA) increased by 15.9%
Peania, 23 May 2024 – Lavipharm Group’s total earnings before interest, taxes, depreciation, and amortisation (EBITDA) during the First Quarter of 2024 posted an increase of 15.9%, amounting to EUR 2.85 million, up from EUR 2.46 million during Q1 2023. The Group’s EBITDA from continuing operations amounted to EUR 2.51 million, up from EUR 2.47 million in the corresponding period last year….
Lavipharm Q1 2024 Key Financial Figures